ACHIEVE LIFE SCIENCES, INC.

ACHV · Nasdaq · SIC 2835: In Vitro & In Vivo Diagnostic Substances
345
SEC Filings

Business Summary

Achieve Life Sciences, Inc. is a clinical-stage biopharmaceutical company focused on developing cytisinicline, a plant-based compound, as a treatment for nicotine dependence, including smoking cessation. The company is pursuing FDA approval for cytisinicline and is exploring its use for additional methods of nicotine dependence beyond smoking. Achieve relies on third-party manufacturers for cytisinicline supply and is focused on commercialization efforts pending regulatory approval.

Next Earnings

Q2 FY2026 — expected 2026-09-18

Key Facts from Earnings Calls

TypeSubjectDetailQuarter
topic_mentionACHVdiscussed_in_filing Regulation
topic_mentionACHVdiscussed_in_filing Regulation
topic_mentionACHVdiscussed_in_filing Regulation
topic_mentionACHVdiscussed_in_filing Regulation

Annual Reports (10-K)

FiledPeriodAccessionSourceFull Text
2026-03-242025-12-310001193125-26-120690EDGAR78K words
2025-03-112024-12-310000950170-25-036831EDGAR—
2024-03-282023-12-310000950170-24-038049EDGAR—
2023-03-162022-12-310001564590-23-003800EDGAR—
2022-03-102021-12-310001564590-22-009485EDGAR—
2021-03-112020-12-310001564590-21-012523EDGAR—
2020-03-132019-12-310001564590-20-010642EDGAR—
2019-03-142018-12-310001564590-19-007838EDGAR—
2018-03-012017-12-310001564590-18-004159EDGAR—
2017-02-232016-12-310001564590-17-002109EDGAR—

Quarterly Reports (10-Q)

FiledPeriodAccessionSourceFull Text
2025-11-062025-09-300001193125-25-268074EDGAR51K words
2025-08-072025-06-300000950170-25-104571EDGAR—
2025-05-132025-03-310000950170-25-069806EDGAR—
2024-11-072024-09-300000950170-24-123375EDGAR—
2024-08-132024-06-300000950170-24-096193EDGAR—
2024-05-092024-03-310000950170-24-056929EDGAR—
2023-11-092023-09-300000950170-23-062028EDGAR—
2023-08-142023-06-300000950170-23-042401EDGAR—
2023-05-092023-03-310000950170-23-019680EDGAR—
2022-11-142022-09-300001564590-22-037646EDGAR—
2022-08-112022-06-300001564590-22-029122EDGAR—
2022-05-122022-03-310001564590-22-019876EDGAR—

Recent Current Reports (8-K)

FiledAccessionSourceFull Text
2026-03-240001193125-26-120687EDGAR3K words
2025-11-060001193125-25-268056EDGAR—
2025-10-070001193125-25-233581EDGAR—
2025-09-110001193125-25-201418EDGAR—
2025-08-070000950170-25-104569EDGAR—
2025-06-270000950170-25-091055EDGAR—
2025-06-060000950170-25-083214EDGAR—
2025-05-130000950170-25-069804EDGAR—
2025-03-110000950170-25-036830EDGAR—
2025-02-100000950170-25-017068EDGAR—

345 total filings indexed. 313 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR

Sector Peers

TKNO — Alpha Teknova, Inc. AWHL — Aspira Women's Health Inc. BMRA — BIOMERICA INC BZYR — BURZYNSKI RESEARCH INSTITUTE INC CDIO — Cardio Diagnostics Holdings, Inc. CLDX — Celldex Therapeutics, Inc. IDXX — IDEXX LABORATORIES INC /DE ICCC — IMMUCELL CORP /DE/

Tags

nicotine-dependence-treatment smoking-cessation

Company Identity

CIK0000949858
TickerACHV
ExchangeNasdaq
SIC2835: In Vitro & In Vivo Diagnostic Substances
IncorporatedDE

Get More Data

This is the free public profile. For structured JSON with full provenance chain, use the API:

JSON Profile Stock Quote AI Readiness Report
Origin Provenance
page leaf: ab38640288105870e05062a306fc84cd9a68f9fda3fb630e41e4940d85d4206b
parent: 39c04562f28866a49e7b0657ae0240a448e09dc3371060f4d9f5da24651c447b
content hash: c19f681dac0ab9d6a07bd8c20b3e6cbeffdb0e3e4915b7dc93f293caa5e9984a
signed: 2026-04-13T04:43:26.431Z
sources: 22 verified data leaves
chain: SEC.gov PEM → origin.rootz.global extraction → this page
verify: sha256(content_hash + parent + timestamp) = leaf